Acrivon advances ACR-2316 into randomized dose expansion in Phase 1/2 trial

• Acrivon Therapeutics advanced ACR-2316 into randomized dose expansion in its ongoing Phase 1/2 trial, based on dose-escalation safety and activity observations.
• Results have already been presented as interim findings from dose escalation; additional updates are expected as the expansion progresses.
• Early outcomes showed durable single-agent anti-tumor activity, including responses in heavily pretreated patients, with tolerability supporting continued development.
• The study will randomize 120 mg versus 160 mg once-daily dosing on a weekly 3-days-on, 4-days-off schedule to support final dose selection.
• Expansion will focus on biomarker-selected solid tumors, led by lung cancer cohorts, aiming to sharpen the benefit-risk profile for later-stage trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608050830PRIMZONEFULLFEED9803960) on August 05, 2026, and is solely responsible for the information contained therein.